Platelet glycoprotein receptor (Null (multiple specific receptors have individual abbreviations, e.g., GPIb-IX, GPIIb/IIIa, GPVI))

Platelet glycoprotein receptors are a diverse group of transmembrane proteins on the platelet membrane, necessary for normal hemostasis and thrombosis[5][1][7]. Key members include glycoprotein Ib-IX (GPIb-IX), the major receptor for von Willebrand factor and a critical mediator of platelet tethering and activation at sites of vascular injury[1][7][8], glycoprotein IIb/IIIa (GPIIb/IIIa, integrin αIIbβ3), responsible for fibrinogen binding and platelet aggregation[3][6][9], and glycoprotein VI (GPVI), the principal collagen receptor for platelets[2][5]. These receptors are major therapeutic targets for antiplatelet drugs in cardiovascular, cerebrovascular, and inflammatory diseases but their inhibition carries a significant bleeding risk[2][6][5][3][9]. The family’s complexity means “platelet glycoprotein receptor” is not a unique target but a group, each member with distinct structure, ligands, and clinical implications.

Other names

Platelet surface glycoproteinPlatelet glycoprotein complexSpecific examples: Glycoprotein Ib-IX (GPIb-IX), Glycoprotein IIb/IIIa (GPIIb/IIIa, integrin αIIbβ3), Glycoprotein VI (GPVI)

Competitive inhibition of fibrinogen binding (GPIIb/IIIa antagonists); Inhibition of platelet aggregation; Blockade of receptor-ligand interaction (e.g., von Willebrand factor binding to GPIb-IX); Prevention of platelet activation (GPVI-targeting agents)